4/7
08:02 am
dnli
Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $32.00 to $34.00. They now have an "outperform" rating on the stock.
Low
Report
Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $32.00 to $34.00. They now have an "outperform" rating on the stock.
4/3
02:11 pm
dnli
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) [Yahoo! Finance]
Low
Report
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) [Yahoo! Finance]
4/3
01:30 pm
dnli
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Low
Report
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
4/1
11:58 am
dnli
This rare disease destroys a child's ability to walk and speak. Could a new drug help? [MSNBC.com]
Low
Report
This rare disease destroys a child's ability to walk and speak. Could a new drug help? [MSNBC.com]
4/1
05:58 am
dnli
They're in a race to save their children with a rare disease. A newly approved drug has given them hope. [MSNBC.com]
Low
Report
They're in a race to save their children with a rare disease. A newly approved drug has given them hope. [MSNBC.com]
3/31
08:49 pm
dnli
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
Low
Report
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
3/30
01:40 am
dnli
Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA Nod - What's Changed [Yahoo! Finance]
Low
Report
Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA Nod - What's Changed [Yahoo! Finance]
3/26
01:49 pm
dnli
Denali Therapeutics (DNLI) had its price target raised by Morgan Stanley from $40.00 to $42.00. They now have an "overweight" rating on the stock.
Low
Report
Denali Therapeutics (DNLI) had its price target raised by Morgan Stanley from $40.00 to $42.00. They now have an "overweight" rating on the stock.
3/26
11:52 am
dnli
Denali Therapeutics (DNLI) had its price target raised by The Goldman Sachs Group, Inc. from $35.00 to $40.00. They now have a "buy" rating on the stock.
Medium
Report
Denali Therapeutics (DNLI) had its price target raised by The Goldman Sachs Group, Inc. from $35.00 to $40.00. They now have a "buy" rating on the stock.
3/26
10:49 am
dnli
Denali Therapeutics (DNLI) had its price target raised by Stifel Nicolaus from $34.00 to $41.00. They now have a "buy" rating on the stock.
Medium
Report
Denali Therapeutics (DNLI) had its price target raised by Stifel Nicolaus from $34.00 to $41.00. They now have a "buy" rating on the stock.
3/26
08:02 am
dnli
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $36.00 to $38.00. They now have a "buy" rating on the stock.
High
Report
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $36.00 to $38.00. They now have a "buy" rating on the stock.
3/26
08:02 am
dnli
Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $29.00 to $32.00. They now have an "outperform" rating on the stock.
High
Report
Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $29.00 to $32.00. They now have an "outperform" rating on the stock.
3/26
08:02 am
dnli
Denali Therapeutics (DNLI) had its price target raised by HC Wainwright from $32.00 to $42.00. They now have a "buy" rating on the stock.
High
Report
Denali Therapeutics (DNLI) had its price target raised by HC Wainwright from $32.00 to $42.00. They now have a "buy" rating on the stock.
3/26
06:58 am
dnli
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript [Seeking Alpha]
Low
Report
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript [Seeking Alpha]
3/25
05:18 pm
dnli
Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch Boost [Yahoo! Finance]
High
Report
Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch Boost [Yahoo! Finance]
3/25
11:50 am
dnli
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Medium
Report
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
3/24
10:00 am
dnli
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
Low
Report
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
3/19
11:11 am
dnli
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts [Yahoo! Finance]
Low
Report
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts [Yahoo! Finance]
3/15
07:26 am
dnli
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build [Yahoo! Finance]
Low
Report
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build [Yahoo! Finance]
3/13
04:22 pm
dnli
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? [Yahoo! Finance]
Neutral
Report
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? [Yahoo! Finance]
3/13
12:54 am
dnli
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains [Yahoo! Finance]
Low
Report
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains [Yahoo! Finance]
3/2
08:02 pm
dnli
Denali Therapeutics (DNLI) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Medium
Report
Denali Therapeutics (DNLI) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/2
08:03 am
dnli
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $32.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $32.00 to $36.00. They now have a "buy" rating on the stock.
2/26
04:22 pm
dnli
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
2/26
04:01 pm
dnli
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Low
Report
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights